Compare EFSC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSC | MESO |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | Australia |
| Employees | 1418 | 81 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | EFSC | MESO |
|---|---|---|
| Price | $65.84 | $13.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $66.33 | N/A |
| AVG Volume (30 Days) | ★ 220.0K | 151.7K |
| Earning Date | 04-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.22 | $629.74 |
| Revenue Next Year | $3.77 | $30.65 |
| P/E Ratio | $11.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.18 | $10.32 |
| 52 Week High | $66.18 | $21.50 |
| Indicator | EFSC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 69.45 | 38.09 |
| Support Level | $52.48 | N/A |
| Resistance Level | N/A | $16.11 |
| Average True Range (ATR) | 1.38 | 0.45 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 84.02 | 2.65 |
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.